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Strengths and limitations of this study
 ► This review brings together a number of recent trials 
with earlier trials so that there is a sizeable sum of 
evidence on which to assess the effectiveness of ra-
diofrequency denervation (RD) for back pain.
 ► Due to the invasive nature of the procedure, it is diffi-
cult to perform truly patient or provider- blinded trials 
and this brings some uncertainty around findings.
 ► There is limited reporting of long- term outcomes 
(>6 months) for the effectiveness of RD.
AbStrACt
Objectives To assess the effectiveness of radiofrequency 
denervation (RD) of lumbosacral anatomical targets for the 
management of chronic back pain.
Design Systematic review and meta- analysis of 
randomised controlled trials (RCTs).
Methods A database search (Medline, Medline in 
Process, Embase, CINHAL and the Cochrane library) 
was conducted from January 2014 to April 2019 for 
placebo or no- treatment controlled trials of RD for the 
management of chronic back pain. Included trials were 
quality assessed using the Cochrane Risk- of- Bias Tool 
and the quality of outcomes assessed using the Grading 
of Recommendations, Assessment, Development and 
Evaluations (GRADE) approach. Meta- analysis was 
conducted to calculate mean difference (MD) in post- 
treatment Pain Score.
results Nineteen RCTs were included in the review. 
There appears to be short- term pain relief (1–3 months) 
provided by RD of the sacroiliac joint (five trials, MD −1.53, 
CI −2.62 to 0.45) and intervertebral discs (four trials, MD 
−0.98, CI −1.84 to 0.12), but the placebo effect is large 
and additional intervention effect size is small (<1 on an 
11 point (0–10) Pain Scale). Longer- term effectiveness (>6 
months) is uncertain.
Conclusions RD of selected lumbosacral targets appears 
to have a small, short- term, positive effect for the 
management of patients with chronic back pain. However, 
the quality of evidence for the majority of outcomes is low 
or very low quality and there is still a degree of uncertainty, 
particularly around the duration of effect.
IntrODuCtIOn
Back pain is an extremely common symptom 
experienced by people of all ages, and can 
be attributed to a wide variety of disease 
processes.1 2 Low back pain is now the leading 
cause of disability worldwide and back pain 
is associated with a substantial economic 
burden, with high medical and societal costs.3 
Studies have shown that a large proportion of 
medical costs come from hospital admissions 
and physical therapy for the management of 
back pain.4 However, there are also indirect 
costs associated with chronic or recurrent 
back pain that are difficult to quantify relating 
to work absenteeism and related produc-
tivity.1 3 4 In many cases, back pain is non- 
specific, or structural pathology amenable to 
surgical correction cannot be identified.5–7 
Hence, patients and practitioners continue to 
seek non- surgical alternatives for the manage-
ment of back pain.
Radiofrequency denervation (RD) involves 
the application of an alternating electric 
current (250–500 kHz) via a needle probe 
to induce a highly localised rise in tissue 
temperature at the needle tip.8 The needle 
tip is usually placed under fluoroscopic guid-
ance to enable selective ablation of sensory 
nerve branches that supply facet joints, sacro-
iliac joint or other structures that comprise 
the lumbosacral spine. RD would, therefore, 
offer relief of pain by attenuating sensory 
signals from the lumbosacral spine.9
Despite its use for over 20 years,10 the effec-
tiveness of RD targeted at the anatomy of 
the lumbosacral spine is not yet established, 
with randomised controlled trials (RCTs) 
continuing to be performed. A number of 
trials have been published since the publica-
tion of the last high- quality review in 201511 
and our systematic review aimed to bring 
together this evidence in an attempt to eval-
uate whether RD is an effective intervention 
for the management of chronic non- specific 
back pain.
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Figure 1 Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses flow diagram.
MAterIAlS AnD MethODS
Search strategy
A search was conducted in Medline, Medline in Process, 
Embase, CINHAL and the Cochrane library from January 
2014 to April 2019 (online supplementary appendix 1). 
Previous systematic reviews were used to obtain additional 
relevant studies published before 2014.
Inclusion criteria
RCTs comparing RD of the spine with a control in patients 
with back pain with or without sciatica were included. 
Only trials of radiofrequency procedures for the purpose 
of ablating or denaturing sensory nerve branches or noci-
ceptors that supply the lumbosacral spine were considered 
for inclusion. Trials of pulsed Radiofrequency (RF),12 or 
other forms of ‘neuromodulatory’ procedures that do not 
aim to ablate or denature these targets, were excluded 
from the review. Control groups where there was no active 
treatment were considered for inclusion but trials with 
potentially effective comparators, for example, cortico-
steroid injections, were excluded. Only trials of patients 
with back pain without a definite or surgically remediable 
cause (chronic non- specific back pain) were included 
in the review. The outcome for the review was patient- 
reported Pain Score, for example, Visual Analogue Scale 
or Numeric Rating Scale.
Data collection and quality assessment
Trial characteristics were recorded from included studies. 
Study results were extracted independently by two authors 
(MEC and PT), with any disagreements resolved by 
consensus. The overall strength of evidence was assessed 
using the GRADE approach.13 Risk of bias was assed using 
the Cochrane Risk- of- Bias Tool.14 Any outcome where 
more than half of trials were considered to have a high or 
unclear risk of bias was downgraded. Outcomes were also 
downgraded where heterogeneity in the meta- analysis was 
greater than 50%. Optimal sample size was taken to be 
85 participants per study arm (as calculated in the Juch 
et al trial)15 and studies with less than 170 participants, 
and/or where the 95% CIs included the line of no effect, 
were downgraded for imprecision. Publication bias was 
assessed using funnel plots and outcomes downgraded 
where there was a high certainty of publication bias.
Data analysis
Meta- analyses were conducted in RevMan16 with random 
effects models since the included studies investigated 
effectiveness in different population groups with varying 
intervention and control group treatments. Pain Score at 
1–3 months was taken as the primary outcome (longest 
time point used for studies reporting multiple time 
points), allowing outcome from a larger number of 
studies to be combined. Pain Score data were reported 
on a 0–10- point scale (Visual Analogue Scale or Numeric 
Rating Scale) in all studies and the mean difference 
(MD) was, therefore, calculated without standardisation 
as done in the previous Cochrane review.11 Studies with 
different spinal targets, for example, facet joints, sacro-
iliac joints or intervertebral disc, were separated in the 
analysis. A sensitivity analysis was conducted to check the 
validity of findings by removing studies considered to 
have a particularly high risk of bias. Subgroup analysis to 
explore study heterogeneity was not conducted because 




The search identified 922 citations of which 229 were 
duplicates. Studies were excluded as shown in figure 1. 
Of the 693 citations reviewed, 8 new trials were identified 
as well as 11 from a previous Cochrane review.11 Exclu-
sions were made as shown in figure 1. Nineteen trials 
were included in the review and their characteristics are 
shown in online supplementary appendix 2. Trials investi-
gated the effectiveness of RD of the facet joint (supplied 
by medial branch of the dorsal spinal ramus),15 17–24 the 
sacroiliac joints,15 25–28 the intervertebral discs29–33 or verte-
bral end plate (supplied by the basivertebral nerve).34 
The majority of trials used a sham- control group but one 
large trial compared RD with no treatment (both groups 
received an exercise programme) and one small trial 
compared RD plus conventional medical with conven-
tional medical management alone (including self- care, 
medications and physical and cognitive therapy).
Study quality
Sham- controlled trials generally appear to have conducted 
adequate randomisation but allocation concealment was 
often unclear. Processes were in place to blind patients 
and providers and outcome assessors. In some trials, 
maintenance of blinding was unclear as it was evident 
that patients undergoing sham procedures were offered 
RD in case of sham treatment failure. In these cases, 
blinding would have been broken. Most trials did not 
report dropouts and there was unclear risk of attrition 
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Table 1 Results of the meta- analyses of randomised controlled trials
All trials Sham- controlled trials
k N MD (95% CI) I2 GRADE* k N MD (95% CI) I2 GRADE*





59% Low 6 348 −0.63
(−1.39 to 0.12)
66% Low
6 months 4 361 −0.66
(−1.37 to 0.05)
42% Low 3 110 −1.05
(−2.21 to 0.10)
32% Low
1 year 2 291 −0.72
(−2.24 to 0.80)
89% Very low 1 40 −1.50
(−2.21 to 0.79)
NA Very low





83% Low 4 156 −1.89
(−3.45 to 0.34)
87% Very low
6 months 1 228 −0.28
(−1.00 to 0.44)
NA Low
12 months 1 228 −0.19
(−0.92 to 0.54)
NA Low





40% Low 3 144 −0.63
(−1.36 to 0.10)
0% Low
6 months 3 127 −1.74
(−2.58 to 0.91)
0% Low 2 75 −1.63
(−2.58 to 0.68)
0% Low
12 months 1 20 −1.70
(−3.63 to 0.23)
NA Very low 1 20 −1.70
(−3.63 to 0.23)
NA Very low
RD of the vertebral body and end plate
3 months 1 205 −0.34
(−1.09 to 0.41)
NA Moderate 1 205 −0.34
(−1.09 to 0.41)
NA Moderate
6 months 1 205 −0.67
(−1.44 to 0.10)
NA Moderate 1 205 −0.67
(−1.44 to 0.10)
NA Moderate
12 months 1 205 −0.50
(−1.29 to 0.29)
NA Moderate 1 205 −0.50
(−1.29 to 0.29)
NA Moderate
*GRADE assessment of the quality of the evidence.
k, number of trials; MD, mean difference; N, number of participants.
bias. The outcome for this review was Pain Score and 
this was reported in all trials and reporting bias was not 
considered to be an issue in the review. Four trials were 
identified as having high risk of bias and were removed in 
the sensitivity analysis.17 19 24 25
Overall quality of the evidence
The majority of outcomes were graded down for impre-
cision and all outcomes were downgraded for potential 
risk of bias. Consequently, almost all outcomes were 
graded as low quality. However, in some cases, high 
heterogeneity was also present and these outcomes were 
graded as very low quality. Publication bias was suggested 
by asymmetry in a number of the funnel plots. However, 
there was uncertainty due to the small numbers of 
studies and outcomes were not graded down for publi-
cation bias.
Study findings
The results of the meta- analyses are shown in table 1.
RD of the facet joints
Meta- analysis of Pain Scores at 1–3 months post proce-
dure (longest time point used for studies with multiple 
time points) (marked on a 0–10 scale) is shown in figure 2 
and table 1. The effect size was similar when all trials were 
included (seven trials, MD −0.56, CI −1.13 to 0.01) or 
where just the sham- controlled trials were included (six 
trials, MD −0.63, CI −1.39 to 0.12) but the effect was not 
significant for either. We also considered outcomes at 
6 and 12 months, where data were available to explore 
longer term outcomes, but did not find any significant 
effect (table 1).
RD of the sacroiliac joints
Figure 3 shows the meta- analysis of trials for Pain Score 
at 1–3 months (longest time point used for studies with 
multiple time points). There was a significant effect of RD 
for the analysis including all trials (five trials, MD −1.53, 
CI −2.62 to 0.45) or just sham- controlled trials (four trials, 
MD −1.89, CI −3.45 to 0.34). Only one trial15 assessed 
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Figure 2 Post- treatment Pain Score for radiofrequency denervation of the facet joints versus control at 1–3- month follow- up 
(longest time point used for studies with multiple time points).
Figure 3 Post- treatment Pain Score for radiofrequency denervation of the sacroiliac joints versus control at 1–3- month follow- 
up (longest time point used for studies with multiple time points).
outcome at later time points and this showed no signif-
icant difference compared with a no- treatment control 
(table 1).
RD of the intervertebral discs
Pain Score at 1–3 months post treatment was signifi-
cantly lower for RD compared with control in all trials 
(four trials, MD −0.98, CI −1.84 to 0.12) but not for sham- 
controlled trials alone (three trials, MD −0.63, CI −1.36 to 
0.10) (figure 4). Pain Score was significantly lower for RD 
when all trials and sham- controlled trials were considered 
at 6 months but, for one trial assessing outcome at 1 year, 
it was not (table 1).
RD of the vertebral body and end plate
One trial of RD for vertebral body and end plate (basiver-
tebral nerve ablation)34 did not show significant benefits 
of RD compared with sham at 3, 6 or 12 months (table 1).
Sensitivity analysis
Four studies were removed in the sensitivity analysis due 
to a high risk of methodological bias17 19 24 25 and the two 
non- sham- controlled trials were also removed.15 32 After 
the removal of these trials, outcome at 1–3 months for 
facet joint sham trials was still not significant (four trials, 
MD −0.57, CI −1.60 to 0.46) and 1–3 month outcome for 
sacroiliac sham trials became non- significant (three trials, 
MD −1.21, CI −2.59 to 0.16). The facet joint sham trial 
outcome at 6 months also became non- significant (one 
trial, MD 0.18, CI −2.80 to 3.16).
DISCuSSIOn
Main findings
This systematic review presents evidence suggesting that 
RD of the lumbosacral spine may have a small positive 
but short- lived effect in patients with chronic back pain, 
depending on the precise part of the anatomy that is 
being targeted by the procedure. The quality of evidence 
for the majority of findings is low or very low quality and 
there is still a degree of uncertainty around this asser-
tion, particularly around the duration of effect. The size 
of benefit appears to be small (<1 point on a 0–10 Pain 
Scale) and there are limited data for outcomes beyond 6 
months. These assertions apply to RD for sacroiliac joints, 
whereas evidence for benefit to other targets is more 
limited. RD for facet joints did not show a significant 
benefit on 1–3- month outcome. There is a suggestion 
that there may be a benefit of RD for intervertebral discs 
but there is some inconsistency, with insignificant effect 
for short- term outcomes.
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Figure 4 Post- treatment Pain Score for radiofrequency denervation of the intervertebral discs versus control at 1–3- month 
follow- up (longest time point used for studies with multiple time points).
What is also clear from the review is that both treat-
ment and sham/no- treatment groups improved during 
the trials. In the sham- controlled trials, this may, in part, 
be due to placebo effect. However, the large trial by Juch 
et al15 used a ‘no additional treatment’ control (both 
groups received an exercise programme) but all study 
arms improved over time. This may be because a high 
proportion of control study participants actually received 
RD (~30%) due to crossover during the trial. However, 
this may also be explained by self- selection of participants 
who volunteer for research trials,35 and hence are likely to 
make more of an active effort to manage their back pain. 
Such participants may be more likely to engage with, and 
be diligent in, exercise programmes and seek medical 
assistance where needed.
In the trial by Juch et al, control group improvements 
may also be explained by the conservative management 
that they received. The exercise programme employed 
was multidisciplinary and comprised individual sessions 
over 8–12 hours focused on quality of movement and 
behaviour, with access to psychological care. There is 
evidence suggesting that patients with chronic back pain 
can benefit from pain management programmes that are 
of sufficient quality and duration.36 Where patients have 
not received an adequate trial of conservative therapy, 
they may benefit from further exercise programmes 
and other conservative management. It remains unclear 
whether patients who are either unable or unwilling to 
engage with conservative approaches to pain manage-
ment would benefit from RD- based interventions as a 
first- line or isolated modality of treatment. Hence, there 
should be some reservation when considering the use of 
RD treatment as a first- line or isolated modality of pain 
management.
Regression to the mean may also have played a role 
in control group improvements since patients in the 
trial were recruited with elevated pain, responsive to an 
anaesthetic block. Back pain has been shown to have a 
varied aetiology, with some patients experiencing fluc-
tuating levels of pain over time, while other experience 
constant high levels of pain.37 38 For the majority of trials 
that reported it, duration of back pain in participants 
prior to enrolment was 2–5 years and a proportion of 
these was likely to have had high levels of constant pain. 
Some, however, may have been experiencing fluctuating 
or recurrent pain within this period since the actual inclu-
sion criteria for most trials was pain for >3 or 6 months 
based on patient recall. If they were recruited at a point 
where their pain had flared acutely, there would be a 
natural tendency for that painful episode to resolve over 
time.
Strengths and limitations
A major strength of this review is that it collates a larger 
body of evidence than previous systematic reviews, with 
the addition of a number of recent trials and thorough 
assessment of the quality of the evidence. The review is 
able to tentatively answer the question about the effec-
tiveness of RD for back pain; an assertion that, to date, 
has proved to be very difficult due a paucity of evidence 
in this field.
This review uses evidence from a previous Cochrane 
review11 but the inclusion criteria for our review had a 
narrower scope (included only sham- controlled trials or 
conservative management- controlled trials of conven-
tional neuroablative RD). Since the previous review 
appears to be of high quality, and we updated it with a 
thorough search of the literature to date, there is assur-
ance that all relevant trials were included.
A limitation of this review is that it was difficult to truly 
assess risk of bias in trials included in the review. Trial 
integrity rested heavily on the blinding of participants and 
the outcome was likely to be highly subject to patients’ 
preconceptions of the different interventions given. Most 
trials did not report information that providers gave to 
the patients about the different possible treatment arms, 
for example, did providers suggest to patients that RD 
was the effective treatment and that sham or no treat-
ment would be ineffective? Where blinding was broken, 
these viewpoints may have influenced patients’ response. 
In some of the sham- controlled studies, this was clearly 
evident. For example, in some studies, before randomi-
sation, patients were told that, if randomised to sham, 
they could receive RD if they gained no benefit. Where 
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blinding was broken, these opinions were likely to influ-
ence patients’ perception of their pain. In other studies, 
information from providers was not reported and it is 
difficult to assess whether this type of bias occurred.
The review may also be limited in its ability to ascertain 
the technical quality of individual research trials. Even 
when examining the reported trial methodology, it is diffi-
cult to conclusively identify trials that employed proce-
dures that may be more or less successful in denervating 
the specific lumbosacral anatomy. Some aspects of RD 
procedures in earlier trials are considered outdated39 40 
but the advantages of more recent procedures for RD 
remain unproven, and there is no clear evidence of their 
superiority. Sensitivity analysis based on technical quality 
was, therefore, considered unhelpful and not performed.
The review is also limited by the lack of long- term 
data from trials. Most studies do not attempt to blind 
patients for more than 3 months and the longer follow- up 
outcomes are considered to be at higher risk of bias. It 
is still, therefore, unclear whether RD of lumbosacral 
anatomy has long- term benefits for back pain.
Finally, the review is limited in its ability to identify any 
aspects of patient or intervention characteristics that may 
make RD treatment more likely to be beneficial. There 
is, to date, no reliable predictor of benefit on back pain 
for RD procedures based on clinical or imaging find-
ings or diagnostic injections.41 The relative advantages 
of different RD technologies used in included trials (eg, 
‘cooled’25 26 32 and ‘bipolar’30 32 RD) remain to be estab-
lished. Due to the small number of studies at each time 
point, subgroup analysis was not considered appropriate. 
However, the publication of more sham- controlled trials 
and trials comparing different RD technologies may make 
this type of investigation possible. Technical advances 
and advances in knowledge and experience may allow for 
better selection of anatomical targets and patients for RD, 
and hence improve clinical outcomes. It is important that 
these developments are formally assessed and published.
In conclusion, within the limitations in this review 
and the published literature, there appears to be at least 
short- term benefit from RD of selected lumbosacral 
anatomical targets for chronic back pain. However, the 
mean size of effect appears to be small and, overall, clin-
ical significance may be marginal. Hence, chronic back 
pain remains a highly challenging condition to treat.
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